Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NEW YORK, March 02, 2017 -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the Cowen & Company 37th Annual Health Care Conference, taking place March 6-8 at the Boston Marriott Copley Place in Boston Massachusetts.
| Ohr Pharmaceutical Presentation Details | |
| Date: | Monday, March 6 |
| Time: | 4:40pm Eastern Time |
| Location: | Regis Ballroom, 3rd Floor |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as Squalamine or OHR-102), is currently being studied as an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
